NICHOLAS J. LOWE, MD, FRCP, FACS , C. ANNE MAXWELL, MB, CHB, AND RICKIE PATNAIK, MD
Different injectable products have highly divergent properties, associated risks, and injection requirements. The der- masurgeon should be suitably experienced to select and use these products correctly.
Martin Duracinsky, Pascale Leclercq, Susan Herrmann, Marie-Odile Christen, Marc Dolivo, Cécile Goujard and Olivier Chassany
This study demonstrated, in real-life conditions and on a large sample, that PLLA injections were feasible, efficient, and safe when performed by trained physicians.
Krista Bohnert, BS, Andrew Dorizas, MD, Paul Lorenc, MD, and Neil S. Sadick, MD
At the 12-month follow-up, there was a statistically significant increase of skin elasticity and hydration in PLLA-treated subjects and a decrease in transepidermal water loss in both groups. Pigmentation, erythema, and pore size were significantly decre
CYNTHIA BARTUS, MD, C. WILLIAM HANKE, MD, AND ELIZABETH DARO-KAFTAN, PHD
Important lessons have been learned in the use of injectable PLLA that have helped reduce the frequency of adverse events and make it desirable for restoring facial volume (Table 1). The importance of diffuse distribution of the injectable PLLA suspension